Your browser is no longer supported. Please, upgrade your browser.
CATB Catabasis Pharmaceuticals, Inc. daily Stock Chart
CATB [NASD]
Catabasis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.23 Insider Own0.57% Shs Outstand17.90M Perf Week-4.02%
Market Cap116.18M Forward P/E- EPS next Y-1.55 Insider Trans0.00% Shs Float16.95M Perf Month-6.26%
Income-28.20M PEG- EPS next Q-0.46 Inst Own44.40% Short Float4.50% Perf Quarter41.23%
Sales- P/S- EPS this Y54.10% Inst Trans0.11% Short Ratio3.57 Perf Half Y6.45%
Book/sh3.38 P/B1.91 EPS next Y18.10% ROA-58.40% Target Price- Perf Year-15.26%
Cash/sh3.05 P/C2.11 EPS next 5Y- ROE-66.00% 52W Range2.74 - 7.81 Perf YTD8.97%
Dividend- P/FCF- EPS past 5Y31.70% ROI- 52W High-17.54% Beta1.76
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low135.04% ATR0.43
Employees27 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)44.94 Volatility5.64% 6.65%
OptionableYes Debt/Eq0.00 EPS Q/Q19.80% Profit Margin- Rel Volume0.36 Prev Close6.49
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume213.52K Price6.44
Recom1.00 SMA20-6.05% SMA500.18% SMA20017.45% Volume77,030 Change-0.77%
Oct-05-17Reiterated Oppenheimer Outperform $4 → $7
Feb-02-17Downgrade Citigroup Buy → Neutral
Dec-22-16Initiated H.C. Wainwright Buy $14
Jun-08-16Reiterated Wedbush Outperform $27 → $17
Jul-20-15Initiated Wedbush Outperform $27
Jul-20-15Initiated Oppenheimer Outperform $28
Jul-20-15Initiated Citigroup Buy $21
Jun-29-20 04:10PM  
Jun-15-20 08:16PM  
Jun-12-20 08:00AM  
May-12-20 04:10PM  
08:00AM  
May-07-20 09:30AM  
Apr-28-20 08:00AM  
Apr-17-20 08:00AM  
Mar-27-20 03:22AM  
Mar-25-20 08:00AM  
Mar-24-20 04:00PM  
Mar-18-20 08:00AM  
Mar-14-20 09:32AM  
Mar-10-20 08:05AM  
06:30AM  
Feb-25-20 08:00AM  
Feb-21-20 08:00AM  
Feb-03-20 04:05PM  
Jan-30-20 09:00AM  
Jan-29-20 04:01PM  
06:10AM  
Jan-09-20 04:09PM  
Jan-08-20 08:00AM  
Dec-24-19 06:15AM  
Dec-23-19 02:15PM  
Dec-16-19 08:00AM  
Nov-25-19 06:45PM  
Nov-18-19 06:53AM  
Nov-07-19 08:05AM  
Oct-24-19 08:00AM  
Oct-19-19 09:26AM  
Oct-18-19 08:00AM  
Oct-05-19 08:00AM  
Sep-30-19 04:05PM  
Sep-27-19 08:00AM  
Sep-26-19 08:00AM  
Sep-25-19 08:00AM  
Sep-19-19 10:13AM  
Aug-20-19 10:58AM  
Aug-09-19 05:04PM  
Aug-08-19 08:05AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Jul-25-19 08:30AM  
Jul-15-19 03:08PM  
Jun-27-19 08:00AM  
Jun-21-19 09:45AM  
Jun-18-19 08:00AM  
Jun-07-19 09:24AM  
May-15-19 06:33PM  
08:38AM  
May-14-19 08:05AM  
May-02-19 08:00AM  
Apr-30-19 08:00AM  
Apr-26-19 03:26PM  
Apr-12-19 11:34AM  
Apr-01-19 08:00AM  
Mar-26-19 12:11PM  
08:07AM  
Mar-19-19 12:26PM  
Mar-18-19 09:02AM  
Mar-14-19 06:09PM  
08:30AM  
08:05AM  
Mar-13-19 08:00AM  
Mar-08-19 09:54AM  
Mar-07-19 08:57AM  
08:51AM  
Mar-06-19 01:56PM  
Feb-28-19 08:00AM  
Feb-19-19 08:00AM  
Feb-14-19 08:00AM  
Feb-06-19 09:00AM  
08:23AM  
Feb-05-19 04:01PM  
Jan-29-19 07:55AM  
Jan-15-19 11:10AM  
Jan-14-19 01:42AM  
Jan-11-19 09:30AM  
Jan-08-19 08:38AM  
Jan-04-19 08:00AM  
Jan-03-19 08:08AM  
Dec-31-18 04:31PM  
Dec-24-18 08:00AM  
Dec-18-18 08:12AM  
Dec-12-18 02:22AM  
Nov-28-18 08:55AM  
Nov-27-18 08:00AM  
Nov-16-18 05:48PM  
Nov-15-18 09:26AM  
Nov-13-18 08:15AM  
08:05AM  
07:45AM  
Nov-02-18 08:00AM  
Oct-30-18 08:00AM  
Oct-18-18 08:25AM  
Oct-17-18 02:20PM  
Oct-04-18 09:20AM  
Oct-03-18 08:00AM  
Sep-25-18 08:00AM  
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company also has a preclinical research collaboration with the Jain Foundation to study edasalonexent (CAT-1004) in Dysferlinopathy. The company was founded in 2008 and is based in Cambridge, Massachusetts.